GSK seeks approval for Breo in asthma; Pfizer under fire for event spending;

> GlaxoSmithKline ($GSK) and partner Theravance ($THRX) have U.S. approval to market Breo Ellipta for patients with asthma. Report

> AstraZeneca ($AZN) has filed a lawsuit against Mylan ($MYL) in the U.S. to block a generic version of diabetes drug Onglyza. More

> Bayer has named three employees to new U.S. government relations and external communications roles. Release

> Argentina has approved Sanofi's ($SNY) Lemtrada to treat for multiple sclerosis. Release

> Astellas has appointed Tatjana Dragovic as its VP and regional compliance officer for its Americas region. Report 

> ANI Pharmaceuticals has acquired Lithobid Extended Release tablets from Noven Therapeutics. Release

> The FDA has updated the label of NPS Pharmaceuticals' sole product, Gattex. More

And Finally... Pfizer ($PFE) has agreed to pay a $5,000 fine for failing to report spending on a reception it hosted during the 2012 Democratic National Convention. Story

 

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.